Owning a pharmacy in England vs Wales: Understanding the differences

By Richard Thomas, senior business agent – pharmacy, Christie & Co

When pharmacy buyers begin their search for their next acquisition, the starting point is almost always England. It is the largest market, operates within a familiar regulatory environment and, quite naturally, offers the greatest number of opportunities.

In recent years, however, a recurring question has begun to surface in conversations with buyers: “Should we also be looking at Wales?”

While the Welsh pharmacy market is undeniably smaller, healthcare policy and the structure of the pharmacy contract have evolved in slightly different ways. For buyers planning acquisitions over the next decade, understanding these differences is becoming increasingly important.

A shift in the role of community pharmacy

Across the UK, community pharmacy is gradually evolving from a model focused almost exclusively on dispensing toward one that is more clinical and patient-facing.

In England, initiatives such as Pharmacy First clearly demonstrate the NHS’s intention to expand the role of pharmacists in managing minor illnesses and easing pressure on GP practices. Despite this direction of travel, the English contract still relies heavily on dispensing activity as the primary source of income for most pharmacies.

Wales, by contrast, moved earlier to embed clinical activity more firmly within the pharmacy contract. Over time, the Welsh system has increasingly encouraged pharmacists to deliver consultations, medicines optimisation, and minor ailment services alongside traditional dispensing. This has subtly reshaped both the professional role of the Pharmacist and the income mix within pharmacies.

Dispensing still underpins value

Despite the growing emphasis on clinical care, dispensing remains the financial cornerstone of most pharmacies.

In England, particularly, income continues to be strongly linked to prescription volume and retained margin on medicines. For this reason, buyers assessing acquisition opportunities still place significant weight on monthly item numbers. Pharmacies dispensing more than 10,000 items per month remain among the most attractive assets in the market and typically generate strong demand when they come to market.

The Welsh pharmacy contract places comparatively greater emphasis on consultative, service-led activity. Consultation-based services, including minor ailment treatment and medication reviews, provide remuneration linked to professional input rather than purely dispensing output.

For pharmacists operating within this system, the role increasingly includes clinical assessment and patient consultations alongside the core dispensing function. For buyers, this introduces an additional dimension to assessing operational performance and future potential.

Prescription charges and operational differences

Another notable operational difference between England and Wales is prescription charging.

In England, some patients are required to pay a prescription charge unless they are exempt. This creates an element of administrative burden for pharmacies and can occasionally affect the speed at which prescriptions are collected.

In Wales, prescriptions are free at the point of supply. While this does not dramatically alter the overall economics of a pharmacy, it does remove a potential barrier for patients and can support more consistent dispensing patterns and simpler day-to-day operations.

What buyers continue to look for

Regardless of location, the fundamentals of pharmacy valuations remain broadly consistent.

Buyers continue to focus on sustainable prescription volumes, local demographics, staffing costs, and the level of competition from nearby pharmacies. Across the UK, pharmacies are typically valued using multiples of adjusted EBITDA (earnings before interest, taxes, depreciation, and amortisation), with profitability, location and operational stability remaining the primary drivers of value.

That said, the gradual evolution of pharmacy contracts is beginning to influence buyer thinking. Pharmacies that already demonstrate strong delivery of clinical services may increasingly be viewed as better positioned for the long-term direction of healthcare policy.

Looking ahead

Ultimately, England and Wales are moving toward the same destination: a community pharmacy sector in which pharmacists play a more visible role in delivering frontline healthcare.

England will continue to dominate in terms of transaction volume and opportunity, but Wales arguably offers a preview of how pharmacy income may shift further toward clinical services and consultations in the years ahead.

For buyers willing to expand their search geographically, the Welsh pharmacy market may represent an interesting – occasionally overlooked – and potentially undervalued – opportunity.